Reblozyl (luspatercept) coverage
Cigna coverage policy governing prior authorization, clinical criteria, dosing, and documentation requirements for Reblozyl (luspatercept-aamt) for beta-thalassemia, myelodysplastic syndromes (MDS), and MDS/MPN with ring sideroblasts; applies to Cigna-administered health benefit plans.
Beta Thalassemia criteria updated to require that the patient has not received a gene therapy for transfusion dependent beta-thalassemia in the past (examples provided: Zynteglo, Casgevy).
Criteria for patients currently receiving Reblozyl were added for beta-thalassemia, MDS, and MDS/MPN indications with defined approval durations and response definitions.
Coverage criteria and dosing information were added for Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm indications.
Documentation requirements were added for coverage of transfusion dependent beta-thalassemia, MDS, and MDS/MPN.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.